Janux Therapeutics Inc expected to post a loss of 39 cents a share - Earnings Preview
08/03/2024 20:23
* Janux Therapeutics Inc JANX.OQ JANX.O is expected
to show a
fall in quarterly revenue when it reports results on March 10
(estimated) for the period ending December 31 2023
* The San Diego California-based company is expected to
report a
74.0% decrease in revenue to $739.25 thousand from $2.85 million
a year ago, according to the mean estimate from 4 analysts,
based on LSEG data.
* LSEG's mean analyst estimate for Janux Therapeutics Inc
is for
a loss of 39 cents per share.
* The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 6 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Janux
Therapeutics Inc is $30.00, below its last closing price
of $40.61.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Sep. 30 2023 -0.45 -0.47 -0.25 Beat 46.8
Jun. 30 2023 -0.50 -0.52 -0.42 Beat 18.8
Mar. 31 2023 -0.49 -0.49 -0.42 Beat 14.6
Dec. 31 2022 -0.50 -0.49 -0.39 Beat 19.8
Sep. -0.50 -0.49 -0.40 Beat 17.9
30 2022
Jun. 30 2022 -0.35 -0.37 -0.41 Missed -10.4
Mar. 31 2022 -0.37 -0.37 -0.32 Beat 13
Dec. 31 2021 -0.30 -0.31 -0.33 Missed -7.4
This summary was machine generated March 8 at 20:23 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)